中国麻风皮肤病杂志 ›› 2020, Vol. 36 ›› Issue (12): 718-721.doi: 10.12144/zgmfskin202012718

• 论著 • 上一篇    下一篇

利妥昔单抗治疗天疱疮六例并文献复习

杨宝琦,张朝霞,陈明飞,王娜,颜潇潇,杨青,潘付堂,王广进,杜东红,吴梅,施仲香,张福仁
  

  1. 山东第一医科大学附属皮肤病医院（山东省皮肤病医院），山东省皮肤病性病防治研究所，济南，250022
  • 出版日期:2020-12-15 发布日期:2020-12-03
  • 通讯作者: 张福仁，E-mail: zhangfuren@hotmail.com

Treatment of pemphigus with rituximab: report of six cases and literature review

YANG Baoqi, ZHANG Zhaoxia, CHEN Mingfei, WANG Na, YAN Xiaoxiao, YANG Qing, PAN Futang, WANG Guangjin, DU Donghong, WU Mei, SHI Zhongxiang, ZHANG Furen   

  1. Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China

  • Online:2020-12-15 Published:2020-12-03
  • Contact: ZHANG Furen, E-mail: zhangfuren@hotmail.com

PDF (PC)

194

摘要： 目的：评价利妥昔单抗治疗天疱疮的疗效和安全性并对相关文献进行复习。方法：对采用利妥昔单抗治疗并随访至少1年的天疱疮患者的临床资料和国内外相关文献进行分析。结果：2013-2019年我院共应用利妥昔单抗治疗天疱疮6例，其中1例为初治患者，5例为病情复发的患者。剂量方案：1例采用淋巴瘤方案，5例采用类风湿关节炎方案。经过2~71个月随访，6例患者中停止治疗后完全缓解2例，治疗中完全缓解3例，出院后因肺部感染死亡1例。最新国内外指南和专家共识已经将利妥昔单抗列为天疱疮的一线治疗药物。结论：利妥昔单抗治疗顽固性天疱疮有效，可达到病情长期缓解的目的，但是需要警惕感染风险。

关键词: 天疱疮, 利妥昔单抗, 疗效, 安全性

Abstract: Objective: To evaluate the efficacy and safety of rituximab in the treatment of pemphigus and to review the literature. Methods: Clinical data of pemphigus patients treated with rituximab and followed up for at least one year were retrospectively analyzed. The domestic and foreign relevant literature was analyzed. Results: A total of six cases of pemphigus were treated with rituximab in our hospital from 2013 to 2019. One case was in the initial treatment while five cases were in the period of relapse. One case was treated with lymphoma regimen and five cases were treated with rheumatoid arthritis regimen. After 2-71 months of follow-up, two cases got complete remission off therapy while three cases got complete remission on therapy and one case died of pulmonary infection after discharge. Rituximab was found to be a first-line treatment for pemphigus in the latest domestic and international guidelines and expert consensuses. Conclusion: Rituximab is effective in the treatment of refractory pemphigus and can make the patients achieve long-term remission. Much attention should be paid to the risk of infection.

Key words: pemphigus, rituximab, effectiveness, safety